Citations

Showing 10 of 108104 citations.

Histopathologic features of necrobiosis lipoidica
Johnson, Emma F. , Patel, Meera H. , Brumfiel, Caitlin M. , Severson, Kevin J. , Bhullar, Puneet , Boudreaux, Blake , Butterfield, Richard , DiCaudo, David J. , Nelson, Steven A. , Pittelkow, Mark R. , Mangold, Aaron R. , Johnson, Emma , Mangold, A R

Mayo Clinic

Journal of Cutaneous Pathology | April 11, 2022 | Volume: 49 | Issue: 8 | Pages: 692-700

10.1111/cup.14238 | PMID 35403265 Get It

AbstractBackgroundNecrobiosis lipoidica (NL) is an uncommon granulomatous dermatosis that can occur in patients with or without associated diabetes mellitus (DM). Prior studies have attempted to determine distinctive histopathologic features of NL in patients with and without DM.MethodsA retrospective review of 97 patients with NL was performed to determine the similar and distinctive histopathologic features in patients with DM and without DM.ResultsOf the 97 patients, 32% (n = 31) had DM. Epidermal acanthosis was seen more commonly in diabetics than nondiabetics (32.3% vs. 12.1%; p = 0.017). Naked (sarcoidal/tuberculoid) granulomas were more frequently observed in nondiabetics than diabetics (22.7% vs. 3.2%; p = 0.016). Eosinophils were more common in nondiabetics than diabetics (38.5% vs. 9.7%; p = 0.004), while neutrophilic infiltration was more common in diabetics than nondiabetics (45.2% vs. 17.5%; p = 0.004).ConclusionsThis study corroborates well‐documented histopathologic features of NL and shows distinctive histopathologic features of NL among patients with DM‐I, DM‐II, and without DM. These results support the hypothesis that there are different underlying drivers of NL between diabetics and nondiabetics.
Global Transcriptomic Profiling Identifies Differential Gene Expression Signatures Between Inflammatory and Noninflammatory Aortic Aneurysms
Hur, Benjamin, Koster, Matthew J. , Jang, Jin Sung , Weyand, Cornelia M. , Sung, Jaeyun , Sung, Jaeyun , Koster, Matthew J , Warrington, Kenneth J.

Mayo Clinic

Arthritis & Rheumatology | April 11, 2022 | Volume: 74 | Issue: 8 | Pages: 1376-1386

10.1002/art.42138 | PMID 35403833 Get It

ObjectiveTo identify hallmark genes and biomolecular processes in aortitis using high‐throughput gene expression profiling, and to provide a range of potentially new drug targets (genes) and therapeutics from a pharmacogenomic network analysis.MethodsBulk RNA sequencing was performed on surgically resected ascending aortic tissues from inflammatory aneurysms (giant cell arteritis [GCA] with or without polymyalgia rheumatica, n = 8; clinically isolated aortitis [CIA], n = 17) and noninflammatory aneurysms (n = 25) undergoing surgical aortic repair. Differentially expressed genes (DEGs) between the 2 patient groups were identified while controlling for clinical covariates. A protein–protein interaction model, drug–gene target information, and the DEGs were used to construct a pharmacogenomic network for identifying promising drug targets and potentially new treatment strategies in aortitis.ResultsOverall, tissue gene expression patterns were the most associated with disease state than with any other clinical characteristic. We identified 159 and 93 genes that were significantly up‐regulated and down‐regulated, respectively, in inflammatory aortic aneurysms compared to noninflammatory aortic aneurysms. We found that the up‐regulated genes were enriched in immune‐related functions, whereas the down‐regulated genes were enriched in neuronal processes. Notably, gene expression profiles of inflammatory aortic aneurysms from patients with GCA were no different than those from patients with CIA. Finally, our pharmacogenomic network analysis identified genes that could potentially be targeted by immunosuppressive drugs currently approved for other inflammatory diseases.ConclusionWe performed the first global transcriptomics analysis in inflammatory aortic aneurysms from surgically resected aortic tissues. We identified signature genes and biomolecular processes, while finding that CIA may be a limited presentation of GCA. Moreover, our computational network analysis revealed potential novel strategies for pharmacologic interventions and suggests future biomarker discovery directions for the precise diagnosis and treatment of aortitis.
Neurogenic thoracic outlet syndrome in the overhead and throwing athlete: A narrative review
Troyer, Wesley , Gardner, James E. , Bowers, Robert L.

Mayo Clinic

PM&R | April 11, 2022 | Volume: 15 | Issue: 5 | Pages: 629-639

10.1002/pmrj.12816 | PMID 35403345 Get It

AbstractThoracic outlet syndrome is an important cause of shoulder pain and dysfunction due to compression of neurovascular structures as they traverse the thoracic outlet. Symptoms are most commonly due to compression of the brachial plexus called neurogenic thoracic outlet syndrome (nTOS). Throwing athletes are at increased risk of nTOS because of a variety of biomechanical factors. However, because nTOS symptoms are often nonspecific, delayed diagnosis is common. Neurogenic thoracic outlet largely remains a diagnosis of exclusion with advanced imaging ruling out vascular involvement and diagnostic injections gaining favor in helping localize sites of compression. Although rehabilitation alone may improve symptoms in some athletes, many require surgical treatment for long‐term relief. This generally entails decompression of the thoracic outlet by some combination of muscle release, brachial plexus neurolysis, and first rib resection. Outcomes tend to be successful in athletes with most achieving resolution of symptoms and return to athletic activity. NTOS is an important cause of shoulder pain and dysfunction in throwing athletes. The history and physical examination should focus on activities that exacerbate symptoms. Treatment of nTOS generally requires surgical intervention and allows throwing athletes to return to sport.
Sequential organ failure assessment score improves survival prediction for left ventricular assist device recipients in intensive care
Chatterjee, Subhasis , Keegan, Mark T. , Passe, Melissa, Loftsgard, Theodore O. , Murphree, Dennis H. , Stulak, John M., Dunlay, Shannon M. , Passe, Melissa A, Loftsgard, Theodore, Jentzer, Jacob C. , Kashyap, Rahul

Mayo Clinic

Artificial Organs | April 11, 2022 | Volume: 46 | Issue: 9 | Pages: 1856-1865

10.1111/aor.14254 | PMID 35403261 Get It

Abstract Background Preoperative risk scores facilitate patient selection, but postoperative risk scores may offer valuable information for predicting outcomes. We hypothesized that the postoperative Sequential Organ Failure Assessment (SOFA) score would predict mortality after left ventricular assist device (LVAD) implantation. Methods We retrospectively reviewed data from 294 continuous‐flow LVAD implantations performed at Mayo Clinic Rochester during 2007 to 2015. We calculated the EuroSCORE, HeartMate‐II Risk Score, and RV Failure Risk Score from preoperative data and the APACHE III and Post Cardiac Surgery (POCAS) risk scores from postoperative data. Daily, maximum, and mean SOFA scores were calculated for the first 5 postoperative days. The area under receiver‐operator characteristic curves (AUC) was calculated to compare the scoring systems' ability to predict 30‐day, 90‐day, and 1‐year mortality. Results For the entire cohort, mortality was 5% at 30 days, 10% at 90 days, and 19% at 1 year. The Day 1 SOFA score had better discrimination for 30‐day mortality (AUC 0.77) than the preoperative risk scores or the APACHE III and POCAS postoperative scores. The maximum SOFA score had the best discrimination for 30‐day mortality (AUC 0.86), and the mean SOFA score had the best discrimination for 90‐day mortality (AUC 0.82) and 1‐year mortality (AUC 0.76). Conclusions We observed that postoperative mean and maximum SOFA scores in LVAD recipients predict short‐term and intermediate‐term mortality better than preoperative risk scores do. However, because preoperative and postoperative risk scores each contribute unique information, they are best used in concert to predict outcomes after LVAD implantation.
Equity
Wieland, Jana, Jordan, Barbara L., Jatoi, Aminah , Wieland, Jana

Mayo Clinic

Cancer | April 11, 2022 | Volume: 128 | Issue: 12 | Pages: 2240-2242

10.1002/cncr.34179 | PMID 35403209 Get It

This editorial comments on an important study by Williams and colleagues. Their study provides direction for future research and for the next steps in clinical cancer care.
Characterizing Extremely Negative Reviews of Ophthalmologists on Yelp.Com
Smith, Jacob F. , Shah, Ami A. , Qureshi, Muhammad B. , Luong, Hanna N. , Adeleye, Olufunmilola , Adams, Olufemi E. , Shen, Joanne F , Adeleye, Olufunmilola

Mayo Clinic

Seminars in Ophthalmology | April 10, 2022 | Volume: 37 | Issue: 5 | Pages: 661-667

10.1080/08820538.2022.2064193 | PMID 35403560 Get It

STAT3 is a biologically relevant therapeutic target in H3K27M-mutant diffuse midline glioma
Day, Charles , Lu, Victor M. , Peterson, Timothy E., Power, Erica A. , Anderson, Jacob B. , Hamdan, Feda H. , Decker, Paul A. , Simons, Renae, Welby, John P. , Siada, Ruby , Ge, Jizhi, Kaptzan, Tatiana, Johnsen, Steven A. , Hinchcliffe, Edward H. , Nesvick, Cody L. , Choi, Jonghoon, Peterson, Timothy, Johnsen, Steven A , Day, Charles A , Power, Erica A , Anderson, Jacob B , Zhang, Liang , Choi, Jonghoon , Decker, Paul A. , Daniels, David J.

Mayo Clinic

Neuro-Oncology | April 9, 2022 | Volume: 24 | Issue: 10 | Pages: 1700-1711

10.1093/neuonc/noac093 | PMID 35397475 Get It

Abstract Background H3K27M-mutant diffuse midline glioma (DMG) is a lethal brain tumor that usually occurs in children. Despite advances in our understanding of its underlying biology, efficacious therapies are severely lacking. Methods We screened a library of drugs either FDA-approved or in clinical trial using a library of patient-derived H3K27M-mutant DMG cell lines with cell viability as the outcome. Results were validated for clinical relevance and mechanistic importance using patient specimens from biopsy and autopsy, patient-derived cell lines, inhibition by gene knockdown and small molecule inhibitors, and patient-derived xenografts. Results Kinase inhibitors were highly toxic to H3K27M-mutant DMG cells. Within this class, STAT3 inhibitors demonstrated robust cytotoxic activity in vitro. Mechanistic analyses revealed one form of activated STAT3, phospho-tyrosine- 705 STAT3 (pSTAT3), was selectively upregulated in H3K27M-mutant cell lines and clinical specimens. STAT3 inhibition by CRISPR/Cas9 knockout, shRNA or small molecule inhibition reduced cell viability in vitro, and partially restored expression of the polycomb repressive mark H3K27me3, which is classically lost in H3K27M-mutant DMG. Putative STAT3-regulated genes were enriched in an H3K27M-knockout DMG cell line, indicating relative gain of STAT3 signaling in K27M-mutant cells. Treatment of patient-derived intracranial xenografts with WP1066, a STAT3 pathway inhibitor currently in clinical use for pediatric brain tumors, resulted in stasis of tumor growth, and increased overall survival. Finally, pSTAT3(Y705) was detected in circulating plasma extracellular vesicles of patients with H3K27M-mutant DMG. Conclusions STAT3 is a biologically relevant therapeutic target in H3K27M-mutant DMG. STAT3 inhibition should be considered in future clinical trials.
Botox for Erectile Dysfunction
Habashy, Engy, Köhler, Tobias S.

Mayo Clinic

The Journal of Sexual Medicine | April 9, 2022 | Volume: 19 | Issue: 7 | Pages: 1061-1063

10.1016/j.jsxm.2022.03.216 | PMID 35414489 Get It

A patient with a novel pathogenic variant in COL5A1 exhibiting prominent vascular and cardiac features
Lavanya, Katta, Mahtani, Karishma , Abbott, Jessica, Jain, Angita , Selvam, Pavalan , Atwal, Herjot, Farres, Houssam , Atwal, Paldeep S. , Atwal, Paldeep S , Lavanya, Katta, Fuller, Jessica M.

Mayo Clinic

American Journal of Medical Genetics Part A | April 9, 2022 | Volume: 188 | Issue: 7 | Pages: 2192-2197

10.1002/ajmg.a.62745 | PMID 35396906 Get It

AbstractThe Ehlers–Danlos Syndromes (EDS) are a group of inherited connective tissue disorders with a worldwide prevalence of 1 in 2500 to 1 in 5000 births irrespective of sex or ethnicity. Fourteen subtypes of Ehlers–Danlos Syndrome (EDS) have been described, each with characteristic phenotypes and associated genes. Pathogenic variants in COL5A1 and COL5A2 cause the classical EDS subtypes. Pathogenic variants in COL3A1 cause vascular EDS. In this case report, we describe a patient with a phenotype resembling that of vascular EDS, caused by a novel pathogenic variant in COL5A1.
Assessing socioeconomic bias in machine learning algorithms in health care: a case study of the HOUSES index
Juhn, Young J. , Ryu, Euijung , King, Katherine S. , Malik, Momin M. , Romero‐Brufau, Santiago , Sohn, Sunghwan , Sharp, Richard R. , Halamka, John , King, Katherine , Malik, Momin , Romero-Brufau, Santiago , Halamka, John D , Sharp, Richard R , Wi, Chung‐Il , Weng, Chunhua

Mayo Clinic

Journal of the American Medical Informatics Association | April 9, 2022 | Volume: 29 | Issue: 7 | Pages: 1142-1151

10.1093/jamia/ocac052 | PMID 35396996 Get It

Abstract Objective Artificial intelligence (AI) models may propagate harmful biases in performance and hence negatively affect the underserved. We aimed to assess the degree to which data quality of electronic health records (EHRs) affected by inequities related to low socioeconomic status (SES), results in differential performance of AI models across SES. Materials and Methods This study utilized existing machine learning models for predicting asthma exacerbation in children with asthma. We compared balanced error rate (BER) against different SES levels measured by HOUsing-based SocioEconomic Status measure (HOUSES) index. As a possible mechanism for differential performance, we also compared incompleteness of EHR information relevant to asthma care by SES. Results Asthmatic children with lower SES had larger BER than those with higher SES (eg, ratio = 1.35 for HOUSES Q1 vs Q2–Q4) and had a higher proportion of missing information relevant to asthma care (eg, 41% vs 24% for missing asthma severity and 12% vs 9.8% for undiagnosed asthma despite meeting asthma criteria). Discussion Our study suggests that lower SES is associated with worse predictive model performance. It also highlights the potential role of incomplete EHR data in this differential performance and suggests a way to mitigate this bias. Conclusion The HOUSES index allows AI researchers to assess bias in predictive model performance by SES. Although our case study was based on a small sample size and a single-site study, the study results highlight a potential strategy for identifying bias by using an innovative SES measure.